Stuttering Therapeutics Market Projected to Gain Significant Value through 2033Posted by Ganesh Shinde on June 14th, 2023 ![]() The global Stuttering Therapeutics Market is estimated to generate a market value of US$ 43 Million in 2023 and a market value of US$ 159.41 Million by 2033, with a CAGR of 14% from 2023 to 2033. In the historical period 2018 to 2022, the market for Stuttering Therapeutics grew at a CAGR of 11%. The market for stuttering therapeutics refers to pharmaceuticals, therapies, and devices used to treat stuttering, a speech disorder characterised by involuntary repetitions or prolongations of sounds, syllables, or phrases, as well as pauses or blocks in speech. The global stuttering therapeutics market is predicted to expand significantly in the future years, owing to increased awareness of the illness, an expanding patient population, and breakthroughs in research and development of new treatments. Several treatments for stuttering are currently accessible, including antipsychotics, antidepressants, and anticonvulsants. These drugs, however, have not been specifically authorised by the FDA for the treatment of stuttering and may have serious negative effects. The most common and successful treatment for stuttering is speech therapy, which involves teaching patients ways to enhance fluency and communication. Other therapies, such as cognitive-behavioral therapy and hypnosis, have had some success. There are also a variety of technologies available to help with stuttering, such as electronic fluency devices, which use changed auditory input to promote speech fluency. Major Players Major players in the market include companies such as Competition Deep Dive, Auspex Pharmaceuticals, Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, AstraZeneca, AbbVie Inc. along with healthcare providers and technology companies among other global players. Key Segments Profiled in the Stuttering Therapeutics Industry Survey Treatment:
Type:
End User:
Like it? Share it!More by this author |